WEDNESDAY, March 1 (HealthDay News) -- The first transdermal patch to treat depression has been approved by the U.S. Food and Drug Administration. The FDA approval was based on results of two double-blind, placebo-controlled studies of Emsam. One study found that six weeks of treatment with Emsam was more effective than a non-medicinal placebo in relieving symptoms of major depression disorder in adults, United Press International reported. The once-a-day patch works by delivering selegiline, a monoamine oxidase inhibitor or MAOI, through the skin and into the bloodstream. Emsam is designed to interact with three brain neurotransmitters that are believed to...
